Quotient And 3 Penny Stocks Insiders Are Buying

U.S. crude oil futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

Better Therapeutics

• The Trade: Better Therapeutics, Inc. BTTX Mark Heinen acquired a total of 2,280 shares at an average price of $1.75. To acquire these shares, it cost around $4 thousand.
• What’s Happening: Better Therapeutics recently announced issuance of US patent covering key features of their prescription digital therapeutics platform.
• What Better Therapeutics Does: Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases.

U.S. Gold

• The Trade: U.S. Gold Corp. USAU Director Luke Norman acquired a total of 8,482 shares at an average price of $4.17. The insider spent around $35.4 thousand to buy those shares.
• What’s Happening: HC Wainwright & Co. recently maintained U.S. Gold with a Buy and lowered the price target from $16.5 to $14.5.
• What U.S. Gold Does: U.S. Gold Corp is a U.S. focused gold exploration and development company. It has a portfolio of exploration properties.

Also check this: US GDP And Other Macro Issues For Wednesday

Don’t forget to check out our premarket coverage here .

Quotient

• The Trade: Quotient Limited QTNT CFO Ali Kiboro acquired a total of 66,666 shares at an average price of $0.30. To acquire these shares, it cost around $20 thousand.
• What’s Happening: Quotient recently announced a $20 million underwritten public offering.
• What Quotient Does: Quotient Ltd is a commercial-stage diagnostics company. It is involved in the development, manufacturing, and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Skillsoft

• The Trade: Skillsoft Corp. SKIL CFO Gary Ferrera acquired a total of 30,000 shares at an average price of $3.61. The insider spent $108.27 thousand to buy those shares.
• What’s Happening: Skillsoft recently reported worse-than-expected Q1 sales results.
• What Skillsoft Does: Skillsoft Corp is a leader in corporate digital learning.